We are a group of research scientists studying oncolytic virotherapy for the treatment of cancer. We aim to identify the best strategies for maximizing the therapeutic benefit of oncolytic viruses by potentiating both the direct oncolytic and tumour-specific, immune-mediated effects of these viruses and to translate our findings into the clinic for the benefit of patients.
